These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16360554)

  • 1. An investigation of clinical studies suggests those with multiple objectives should have at least 90% power for each endpoint.
    Borm GF; Houben RM; Welsing PM; Zielhuis GA
    J Clin Epidemiol; 2006 Jan; 59(1):1-6. PubMed ID: 16360554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generalized concept of power helped to choose optimal endpoints in clinical trials.
    Borm GF; van der Wilt GJ; Kremer JA; Zielhuis GA
    J Clin Epidemiol; 2007 Apr; 60(4):375-81. PubMed ID: 17346612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis and importance of statistical power and sample size in empirical scientific research].
    Klimek KM
    Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple sample size formula for analysis of covariance in randomized clinical trials.
    Borm GF; Fransen J; Lemmens WA
    J Clin Epidemiol; 2007 Dec; 60(12):1234-8. PubMed ID: 17998077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample-size calculations for studies with correlated ordinal outcomes.
    Kim HY; Williamson JM; Lyles CM
    Stat Med; 2005 Oct; 24(19):2977-87. PubMed ID: 16149125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat.
    Matilde Sanchez M; Chen X
    Stat Med; 2006 Apr; 25(7):1169-81. PubMed ID: 16397861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A note on the power of Fisher's least significant difference procedure.
    Meier U
    Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The methods for handling missing data in clinical trials influence sample size requirements.
    Auleley GR; Giraudeau B; Baron G; Maillefert JF; Dougados M; Ravaud P
    J Clin Epidemiol; 2004 May; 57(5):447-53. PubMed ID: 15196614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The reassessment of trial perspectives from interim data--a critical view.
    Bauer P; Koenig F
    Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of underpowered randomized clinical trials in rheumatology.
    Keen HI; Pile K; Hill CL
    J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical analysis of clinical trials.
    Wassertheil-Smoller S; Kim MY
    Semin Nucl Med; 2010 Sep; 40(5):357-63. PubMed ID: 20674595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new and rapid scoring system to assess the scientific evidence from clinical trials.
    Silber S
    J Interv Cardiol; 2006 Dec; 19(6):485-92. PubMed ID: 17107362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variance estimation in clinical studies with interim sample size re-estimation.
    Miller F
    Biometrics; 2005 Jun; 61(2):355-61. PubMed ID: 16011681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data.
    Vickers AJ
    BMC Med Res Methodol; 2005 Nov; 5():35. PubMed ID: 16269081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evidence provided by a single trial is less reliable than its statistical analysis suggests.
    Borm GF; Lemmers O; Fransen J; Donders R
    J Clin Epidemiol; 2009 Jul; 62(7):711-715.e1. PubMed ID: 19171462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mid-course sample size modification in clinical trials based on the observed treatment effect.
    Jennison C; Turnbull BW
    Stat Med; 2003 Mar; 22(6):971-93. PubMed ID: 12627413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.